pomalidomide has been researched along with melphalan in 9 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (melphalan) | Trials (melphalan) | Recent Studies (post-2010) (melphalan) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 8,134 | 1,351 | 1,972 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, S; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lust, JA; Rajkumar, SV; Russell, SJ; Zeldenrust, S | 1 |
| Schots, R | 1 |
| Iida, S | 1 |
| Aerts, JL; Corthals, J; De Keersmaecker, B; Fostier, K; Heirman, C; Schots, R; Thielemans, K; Wilgenhof, S | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M | 1 |
| Abdulhaq, H; Bakker, NA; Dimopoulos, MA; Hájek, R; Ludwig, H; Mateos, MV; Norin, S; Richardson, PG; Schjesvold, FH; Sonneveld, P; Thuresson, M | 1 |
2 review(s) available for pomalidomide and melphalan
| Article | Year |
|---|---|
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
3 trial(s) available for pomalidomide and melphalan
| Article | Year |
|---|---|
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide | 2022 |
4 other study(ies) available for pomalidomide and melphalan
| Article | Year |
|---|---|
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Topics: Amyloid; Amyloidosis; Biomarkers; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Melphalan; Natriuretic Peptide, Brain; Patient Dropouts; Peptide Fragments; Stem Cell Transplantation; Thalidomide; Troponin T | 2010 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dendritic Cells; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2014 |
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Follow-Up Studies; Humans; Melphalan; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Assessment; Transplantation, Autologous | 2023 |